Quoin Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Update
Quoin Pharmaceuticals announced its third-quarter 2026 financial results alongside updates on its clinical pipeline and capital structure.
Stocks · News reference
Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Quoin Pharmaceuticals Ltd. (QNRX)
Filed: 2026-11-04 AccNo: 0001104659-26-122790 Size: 583 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results
Quoin Pharmaceuticals Ltd. announced it will release its financial results for the third quarter ended September 30, 2026, on November 5, 2026.
Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published– Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient– Patient’s Skin Improved from
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
Canaccord Genuity analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $18.
Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe